The Spectrum of Genetic Mutations in Breast Cancer

Asfandyar Sheikh(Dow University of Health Sciences), Syed Ather Hussain(Dow University of Health Sciences), Quratulain Ghori(Jinnah Sindh Medical University), Nida Naeem(Liaquat National Hospital), Abul Fazil(Manipal Academy of Higher Education), Smith Giri(University of Tennessee Health Science Center), Brijesh Sathian(Manipal College of Medical Sciences), Prajeena Mainali(Edward Via College of Osteopathic Medicine), Dalal M. Al Tamimi(King Fahd Hospital of the University)
Asian Pacific Journal of Cancer Prevention
April 3, 2015
Cited by 87Open Access
Full Text

Abstract

Breast cancer is the most common malignancy in women around the world. About one in 12 women in the West develop breast cancer at some point in life. It is estimated that 5%-10% of all breast cancer cases in women are linked to hereditary susceptibility due to mutations in autosomal dominant genes. The two key players associated with high breast cancer risk are mutations in BRCA 1 and BRCA 2. Another highly important mutation can occur in TP53 resulting in a triple negative breast cancer. However, the great majority of breast cancer cases are not related to a mutated gene of high penetrance, but to genes of low penetrance such as CHEK2, CDH1, NBS1, RAD50, BRIP1 and PALB2, which are frequently mutated in the general population. In this review, we discuss the entire spectrum of mutations which are associated with breast cancer.


Related Papers

No related papers found

Powered by citation graph analysis